Neuropsychiatric medicines company Seaport Therapeutics has closed an oversubscribed $225 million Series B financing round. The financing brings the total capital raised by Seaport to $325 million since the company’s launch in April 2024. Seaport will use the proceeds to advance its clinical-stage pipeline of first and best-in-class medicines through important clinical milestones as well […]

City Therapeutics has launched with $135 million in financing and a vision to lead the future of RNA interference (RNAi)-based medicine. Led by executive chair John Maraganore, founding CEO of Alnylam Pharmaceuticals, the startup aims to harness next-generation engineering of small interfering RNAs (siRNAs) – the “trigger” molecules that mediate RNAi – to build a […]

The Healey-Driscoll administration and the Massachusetts Life Sciences Center (MLSC) have announced $21.4 million in tax incentive awards to 19 life sciences companies. The awards, provided through the MLSC’s Tax Incentive Program, are expected to create 1,155 new life sciences industry jobs in Massachusetts. The MLSC Tax Incentive program is offered to companies engaged in life […]

The FDA has approved Cobenify, an oral medication for the treatment of schizophrenia in adults. Cobenify represents the first new class of schizophrenia medicine in several decades and introduces a fundamentally new approach to treating the illness. “Today’s landmark approval of our first-in-class treatment for schizophrenia marks an important milestone for the community, where after more […]

Boston-based Bicara Therapeutics, a clinical-stage biopharma developing therapies for patients with solid tumors, this week announced the closing of its initial public offering which raised gross proceeds of approximately $362 million. Bicara’s lead asset, ficerafusp alfa, is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor (EGFR) directed monoclonal antibody […]